National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cannabidiol is indicated for use as adjunctive therapy of seizures associated with Dravet Syndrome in conjunction with clobazam, for patients two years of age and older.


NCPE Assessment Process Complete
Rapid review commissioned 05/02/2020
Rapid review completed 11/03/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cannabidiol compared with the current standard of care.